CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Xagena Salute

Search results for "Risk of major bleeding"

The ACUITY ( Acute Catheterization and Urgent Intervention Triage strategy ) trial has assessed the potential of the injectable anti-clotting medicine Bivalirudin ( Angiomax ) in patients experiencing ...


Anticoagulant treatment with vitamin K antagonists ( VKAs ) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation ...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


European Xarelto ( Rivaroxaban ) product information has now included guidance for use in patients with atrial fibrillation undergoing cardioversion. The label update is based on findings from the ...


Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and mortality in patients with acute coronary syndrome ( ACS ). Both trials are part ...


The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. Researchers have investigated the efficacy and safety of Ticagrelor ( Brili ...


In addition to Warfarin ( Coumadin ), there are four non-vitamin K antagonist oral anticoagulants ( NOACs ) available for stroke prevention in non-valvular atrial fibrillation ( NVAF ). There are li ...


Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation ...


The results from an independent retrospective comparative study, published in the American Journal of Medicine, have shown that Dabigatran was associated with a more favourable benefit-harm profile th ...


Low-dose Aspirin ( Acetylsalicylic acid ) does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease. The results of the ASPREE ...


At the European Society of Cardiology Congress 2019, researchers from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris, have presented the results from T ...